| Literature DB >> 32508685 |
Magnus Nordmo1, Nils Martin Sønderland1, Odd E Havik2, Dag-Erik Eilertsen1, Jon T Monsen1, Ole Andre Solbakken1.
Abstract
OBJECTIVE: This study investigates the effectiveness of open-ended psychotherapy in a large, naturalistic, and diverse patient cohort using rigorous and multifaceted assessments.Entities:
Keywords: effectiveness; naturalistic; outcome; psychotherapy; representative
Year: 2020 PMID: 32508685 PMCID: PMC7251147 DOI: 10.3389/fpsyt.2020.00384
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Changes in occupational status and diagnosis frequency.
| Number and percentages of patients | |||
|---|---|---|---|
| Pretreatment* | End of treatment** | Two-year follow-up*** | |
| Functioning | 202 (55 %) | 205 (65 %) | 190 (65 %) |
| Non-functioning | 154 (42 %) | 110 (35 %) | 104 (35 %) |
| SCID1 Diagnosis | |||
| Presence of SCID 1 diagnosis | 321 (87 %) | 119 (40 %) | 99 (38 %) |
| Affective disorders | 150 | 56 | 42 |
| Anxiety disorders | 406 | 109 | 84 |
| Somatoform disorders | 117 | 26 | 23 |
| Eating disorders | 31 | 10 | 4 |
| Substance-Related disorder | 9 | 4 | 4 |
| Schizophrenia and other psychotic related disorders | 2 | 3 | 2 |
| SCID2 Diagnosis | |||
| Presence of SCID 2 diagnosis | 200 (54 %) | 84 (28 %) | 58 (22 %) |
| Cluster A | 82 | 31 | 14 |
| Cluster B | 71 | 24 | 21 |
| Cluster C | 169 | 62 | 35 |
| Not Otherwise Specified | 2 | 0 | 1 |
*Percentage from total sample (N = 370).
**Percentage from available occupational (n = 315) and diagnostic (n = 297) post-treatment data.
***Percentage from available occupational (n = 294) and diagnostic (n = 258) follow-up data.
Figure 1Patient attrition.
Figure 2Treatment length.
Figure 3Alluvial diagram of changes in diagnostic and occupational status.
Figure 4Odds ratios comparison to pretreatment.
Measures on symptoms and interpersonal functioning in the treatment phase.
| GSI | IIP Global | |||
|---|---|---|---|---|
| Model 0 | Model 1 | Model 0 | Model 1 | |
| Est | Est | Est | Est | |
| Intercept | 1.33** (.03) | 1.33** (.04) | 1.45** (.03) | 1.46** (.03) |
| Logtime | -.186** (.01) | -.186** (.01) | -.108** (.008) | -.113** (.012) |
| Est | Est | Est | Est | |
| Residual | .14** (.37) | .10** (.32) | .09** (.30) | .07** (.26) |
| Variance in intercept | .31** (.56) | .39** (.63) | .24** (.49) | .027** (.02) |
| Variance in slopes | N/A | .04** (.21) | N/A | .03** (.17) |
| Intercept Slope Corr. | N/A | -.43 | N/A | -.32 |
| BIC | 2714.5 | 2555.8 | 1952.8 | 1798.3 |
Standard error in parenthesis. Estimation performed using Restricted Maximum Likelihood (REML). Model 0 fixates the rate of change for each patient while Model 1 allows for variable changes across patients. Fixed effects are presented with the estimate and standard deviation in parenthesis. Random effects are presented with the variance and standard error in parenthesis. **p < .01.
Figure 5GSI and IIP Global predicted score distributions.
Measures on symptoms and interpersonal functioning in the follow-up phase.
| GSI | IIP Global | |||
|---|---|---|---|---|
| Model 0 | Model 1 | Model 0 | Model 1 | |
| Est | Est | Est | Est | |
| Intercept | .82** (.04) | .82** (.04) | 1.19** (.03) | 1.19** (.03) |
| Logtime | -.009 (.01) | -.008 (.02) | -.042** (.01) | -.043* (.01) |
| Est | Est | Est | Est | |
| Residual | .08** (.28) | .07** (.26) | .07** (.26) | .06** (.23) |
| Variance in intercept | .34** (.58) | .38** (.61) | .28** (.53) | .30** (.55) |
| Variance in slopes | N/A | .03* (.17) | N/A | .02** (.14) |
| Intercept Slope Corr. | N/A | -.32 | N/A | -.22 |
| BIC | 1199.8 | 1191.7 | 996.9 | 995.8 |
Standard error in parenthesis. Estimation performed using Restricted Maximum Likelihood (REML). Model 0 fixates the rate of change for each patient while Model 1 allows for variable changes across patients. Fixed effects are presented with the estimate and standard deviation in parenthesis. Random effects are presented with the variance and standard error in parenthesis. *p < .05 **p < .01.
Clinically significant change using predicted scores.
| Number and Percentages of Patients | ||
|---|---|---|
| Measures and status | Pretreatment to termination of treatment * | Pretreatment to two-year follow-up ** |
| Global Severity Index (SCL-90) | ||
| Recovered | 142 (38 %) | 132 (42 %) |
| Improved | 114 (31%) | 72 (23 %) |
| Unchanged | 107 (29 %) | 103 (32 %) |
| Deteriorated | 6 (1.6 %) | 11 (3.4 %) |
| IIP Global (IIP-64) | ||
| Recovered | 84 (23 %) | 99 (31 %) |
| Improved | 43 (12 %) | 42 (13 %) |
| Unchanged | 234 (63 %) | 167 (53 %) |
| Deteriorated | 9 (2.4 %) | 10 (3.1 %) |
* Percentage from total sample (N = 370).
** Percentage from patients with follow-up measure (n = 318).